Beam Therapeutics Inc. (BEAM) Stock Forecast
Data as of May 2, 2026Healthcare · Current price $31.02 (+2.29%)
Price Target Range
Consensus Price Target Over Time
Analyst Rating Distribution
Last 3 Months
6-Month Trend
Latest Analyst Forecasts
Price targets issued by Wall Street analysts. Upside calculated against today's price.
| Date | Analyst | Firm | Price Target | Upside |
|---|---|---|---|---|
| Jan 21, 2026 | William Pickering | Tudor Pickering | $41.00 | +32.2% |
| Jan 7, 2026 | Michael Yee | UBS | $28.00 | -9.8% |
| May 7, 2025 | Debjit Chattopadhyay | Guggenheim | $55.00 | +77.3% |
| Jan 7, 2025 | William Pickering | Tudor Pickering | $37.00 | +19.3% |
| Nov 6, 2024 | Rick Bienkowski | Leerink Partners | $39.00 | +25.7% |
| Nov 5, 2024 | Kostas Biliouris | BMO Capital | $57.00 | +83.7% |
| Sep 11, 2024 | Benjamin Burnett | Stifel Nicolaus | $69.00 | +122.4% |
| Dec 20, 2022 | Kostas Biliouris | BMO Capital | $66.00 | +112.7% |
Top Analysts Covering BEAM
BEAM vs Sector & Market
| Metric | BEAM | Healthcare Avg | Large Cap Avg |
|---|---|---|---|
| Analyst Rating | 2.25 | 2.24 | 2.41 |
| Analyst Count | 4 | 8 | 18 |
| Target Upside | +31.6% | +1150.2% | +14.9% |
| P/E Ratio | -39.30 | 6.90 | 31.19 |
Revenue Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-06-30 | $5M | $11M | $20M | 8 |
| 2026-09-30 | $7M | $12M | $22M | 4 |
| 2026-12-31 | $7M | $12M | $23M | 7 |
| 2027-03-31 | $9M | $17M | $32M | 4 |
| 2027-06-30 | $9M | $17M | $32M | 6 |
| 2027-09-30 | $9M | $17M | $32M | 4 |
| 2027-12-31 | $11M | $20M | $39M | 7 |
| 2028-12-31 | $113M | $116M | $120M | 13 |
| 2029-12-31 | $192M | $399M | $809M | 12 |
| 2030-12-31 | $342M | $712M | $1.44B | 6 |
EPS Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-06-30 | $-1.50 | $-1.05 | $-0.14 | 9 |
| 2026-09-30 | $-2.42 | $-1.10 | $-0.48 | 3 |
| 2026-12-31 | $-2.54 | $-1.15 | $-0.50 | 7 |
| 2027-03-31 | $-2.16 | $-0.98 | $-0.43 | 3 |
| 2027-06-30 | $-2.17 | $-0.99 | $-0.43 | 3 |
| 2027-09-30 | $-2.18 | $-0.99 | $-0.43 | 4 |
| 2027-12-31 | $-2.26 | $-1.03 | $-0.44 | 3 |
| 2028-12-31 | $-7.57 | $-4.53 | $-2.81 | 11 |
| 2029-12-31 | $-7.29 | $-3.13 | $-1.01 | 4 |
| 2030-12-31 | $-2.58 | $-1.11 | $-0.36 | 4 |
Frequently Asked Questions
What is the analyst consensus for BEAM?
The consensus among 4 analysts covering Beam Therapeutics Inc. (BEAM) is Buy with an average price target of $40.86.
What is the highest price target for BEAM?
The highest price target for BEAM is $69.00, set by Benjamin Burnett at Stifel Nicolaus on 2024-09-11.
What is the lowest price target for BEAM?
The lowest price target for BEAM is $28.00, set by Michael Yee at UBS on 2026-01-07.
How many analysts cover BEAM?
4 analysts have issued ratings for Beam Therapeutics Inc. in the past 12 months.
Is BEAM a buy or sell right now?
Based on 4 analyst ratings, BEAM has a consensus rating of Buy (2.25/5) with a +31.6% upside to the consensus target of $40.86.
What are the earnings estimates for BEAM?
Analysts estimate BEAM will report EPS of $-1.05 for the period ending 2026-06-30, with revenue estimated at $11M.
Related Stock Forecasts
Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.